Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): first results of the CheckMate 8HW study
| Title | Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): first results of the CheckMate 8HW study |
|---|---|
| Description | CA209-8HW Data for ASCO 2024 |
| Organism | Homo sapiens |
| Data Type | Biomarker Data |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA022013 |
| Release Date | 2024-01-20 |
| Submitter | Li Jin (lijin@csco.org.cn) |
| Organization | Shanghai East Hospital |
| Submission Date | 2023-12-13 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX005374-01 | CA209-8HW ASCO 2024 | 91 | Biomarker Data | 55.6 KB | 0 | Controlled |